These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25201034)

  • 1. Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment.
    Golan S; Entin-Meer M; Semo Y; Maysel-Auslender S; Mezad-Koursh D; Keren G; Loewenstein A; Barak A
    BMC Res Notes; 2014 Sep; 7():617. PubMed ID: 25201034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A; Recber M; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
    Miura Y; Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
    Klettner AK; Kruse ML; Meyer T; Wesch D; Kabelitz D; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
    Malik D; Tarek M; Caceres del Carpio J; Ramirez C; Boyer D; Kenney MC; Kuppermann BD
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
    Peng S; Adelman RA; Rizzolo LJ
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous application of bevacizumab and anti-CTGF antibody effectively suppresses proangiogenic and profibrotic factors in human RPE cells.
    Bagheri A; Soheili ZS; Ahmadieh H; Samiei S; Sheibani N; Astaneh SD; Kanavi MR; Mohammadian A
    Mol Vis; 2015; 21():378-90. PubMed ID: 25883524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
    Dinç E; Ayaz L; Kurt AH
    J Ocul Pharmacol Ther; 2018 May; 34(4):346-353. PubMed ID: 29389239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
    Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
    Barzelay A; Lowenstein A; George J; Barak A
    Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab interacts with the VEGF-A/VEGFR-2 signaling pathway in human RPE cells at different levels.
    Ranjbar M; Brinkmann MP; Tura A; Rudolf M; Miura Y; Grisanti S
    Cytokine; 2016 Jul; 83():210-216. PubMed ID: 27163716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
    Eur J Ophthalmol; 2016 Aug; 26(5):425-30. PubMed ID: 27079208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Wang VM; Rosen RB; Meyerle CB; Kurup SK; Ardeljan D; Agron E; Tai K; Pomykala M; Chew EY; Chan CC; Tuo J
    Mol Vis; 2012; 18():2578-85. PubMed ID: 23112570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M; Brinkmann MP; Zapf D; Miura Y; Rudolf M; Grisanti S
    Cell Physiol Biochem; 2016; 38(2):737-47. PubMed ID: 26871551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB; Rho CR; Shin JA; Lyu J; Kang S
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL; Deissler H; Lang GE
    Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
    Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
    Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.